INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Depart...

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 1...

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Derux...

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s...

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro...

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update...

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on We...

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKm...

INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the ...

INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update...

INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on W...

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's...

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases...

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2...

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application f...

INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th...

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd Eu...

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update...

INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference...

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammatio...

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Researc...

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate ...

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumo...

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022...

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Al...

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Ma...

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update...

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on T...

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference...

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate I...

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting...